Story perspectives

Pharma Sales Drop: New Policies Threaten Innovation

10/22/2025

25 5

Summary

Story summary

Adoption of newly launched pharmaceutical products has declined, with only 10% reaching $100 million in US sales within the first year (2020–2024), down from 20% (2015–2019).
The Inflation Reduction Act introduces a Medicare price-setting event that compresses drugs’ lifespans.
Manufacturers respond with strategies like indication stacking to maximize revenue earlier.
The MFN pricing policy raises concerns about innovation and global access, potentially driving steep price reductions and reducing revenue.

1 of 1

Story summary

Adoption of newly launched pharmaceutical products has declined, with only 10% reaching $100 million in US sales within the first year (2020–2024), down from 20% (2015–2019).
The Inflation Reduction Act introduces a Medicare price-setting event that compresses drugs’ lifespans.
Manufacturers respond with strategies like indication stacking to maximize revenue earlier.
The MFN pricing policy raises concerns about innovation and global access, potentially driving steep price reductions and reducing revenue.